Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ESLA
#3526
Estrella Immunopharma, Inc. Common Stock
1.2
2
+0.83%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+0.83%
Monthly Change
+10.91%
6 month change
+29.79%
Year Change
+25.77%
Previous Close
1.2
1
Open
1.2
2
Bid
Ask
Low
1.2
2
High
1.2
2
Volume
1
Markets
US Stock Market
Healthcare
ESLA
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
TTM
Key stats
Total common shares outstanding
5.85 M
2.33 M
35.2 M
—
Valuation ratios
Enterprise value
—
—
36.11 M
149.91 M
Price to earnings ratio
—
—
-4.07
-0.42
Price to sales ratio
—
—
7.93
—
Price to cash flow ratio
—
—
-1.86
-25.78
Price to book ratio
—
—
7.9
-12.16
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-0.01
-0.1
-1.64
-4.99
Return on equity %
0.25
0.44
-1.71
-1.98
Return on invested capital %
-2.2
-24.51
-557.25
361.44
Gross margin %
—
—
100
—
Operating margin %
—
—
-194.49
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
-194.53
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
8.42
0.05
24.65
1.28
Inventory turnover
—
—
—
—
Asset turnover
—
—
0.53
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-0.27
-0.24
-0.59
-0.11
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
0.41
0.01
0.15
0.14
Net current asset value per share
0.52
0.01
0.16
0.18
Tangible book value per share
-0.85
-0.22
0.14
-0.48
Working capital per share
0.46
-0.23
0.16
-0.63
Book value per share
-0.85
-0.52
0.14
-0.48
News
Estrella reports 100% complete response rate in lymphoma trial
Estrella to present phase 1 data on CD19-targeted cell therapy
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting
Estrella Immunopharma closes $8 million registered direct offering
Estrella Immunopharma stock falls after announcing $8 million offering
Estrella Immunopharma raises $8 million through registered offering
Estrella Immunopharma stock rises as cancer therapy advances to Phase II
Estrella’s EB103 advances to Phase II after positive safety data
Estrella Immunopharma stock soars after 100% complete response rate in trial
Estrella’s lymphoma therapy shows 100% response rate in phase I trial
Estrella Immunopharma regains Nasdaq compliance after capital raise
Estrella Immunopharma regains Nasdaq compliance on bid price and market value